Efficacy and Safety of Panlongqi Tablet in Patients With Knee Osteoarthritis

Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Status and phase: Unknown; Phase 3

Conditions: Knee Osteoarthritis

Treatments: Drug: Treatment of Panlongqi placebo; Drug: Treatment of Panlongqi Tablet

Study type: Interventional

Funder types: Other

Identifiers

NCT03327012

PLQ_2016001

Details and patient eligibility

About

This study evaluates the efficacy and safety of Panlongqi tablet compared with placebo in the treatment of knee osteoarthritis in adults.Half of participants will receive Panlongqi tablet in combination,while the other half will receive a Placebo.

Full description

The test group will be given Panlongqi tablet 1.2g three times per day,the control group will be given placebo 1.2g three times per day. The invention will last 4 weeks.

Enrollment: 300 estimated patients

Sex: All

Ages: 40 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1.40-75 years of age (including 40 years and 75 years old), men and women are not limited.

2. western medicine diagnosis of knee osteoarthritis, clinical classification for primary.

3.The severity of the imaging classification of K-L≤Ⅲ; 4. treatment VAS pain scores than 40mm (select the subjects most obvious limb pain symptoms).

5. informed consent form signed by the patient or legal representative.

Exclusion criteria

1. within 3 months prior to the trial, the patients were treated within 1 years.
2. 4 weeks before the treatment, corticosteroids, non steroidal drugs, intra-articular injections or other drugs to improve the condition (such as cartilage protective agents) were used.
3. Swelling of the knee joint.
4. knee synovial crystalline (joint) inflammation, acute inflammatory arthritis, rheumatoid arthritis, metabolic bone disease, psoriatic arthritis, septic arthritis, systemic lupus erythematosus, Sjogren syndrome, vasculitis and other rheumatic diseases caused by inflammatory arthritis and endocrine diseases caused by.
5. the screening period has any disease history or evidence: The basic of serious cardiovascular and cerebrovascular diseases; An active, recurrent peptic ulcer or other hemorrhagic disease risk; Sales and other serious diseases of digestive system; An associated with malignant tumors, blood, or other serious diseases or system;
6. patients who are unable to cooperate or cooperate with other mental disorders.
7. before the screening, any laboratory test indicators meet the following standards: An admission of liver and kidney function showed that ALT and AST is more than 1.5 times the upper limit of the normal value, Cr is more than 1.2 times the upper limit of normal (Reference Research Center laboratory where the range of normal value); An other clinically significant laboratory abnormalities, and the researchers judged not into the group.
8. allergic constitution or allergic to test seven tablets, excipients or similar ingredients;
9. doubt or indeed history of alcohol and drug abuse;
10. pregnant or lactating women or recent planned pregnancies and those who are reluctant to use contraceptives;
11. participants who participated in other clinical trials within the first 3 months.
12. the researchers believe that patients should not participate in this clinical trial.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

300 participants in 2 patient groups, including a placebo group

Treatment of Panlongqi Tablet

Experimental group

Description:

Patients were treated with Panlongqi Tablet.

Treatment:

Drug: Treatment of Panlongqi Tablet

Treatment of Panlongqi Placebo

Placebo Comparator group

Description:

Patients were treated with Panlongqi Placebo Tablet.

Treatment:

Drug: Treatment of Panlongqi placebo